Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11 Avril 2022 - 07:00AM
Leuven, BELGIUM, Boston, MA, US – 11
April 2022 – 7.00 AM CET – Oxurion NV (Euronext Brussels:
OXUR), a biopharmaceutical company developing next generation
standard of care ophthalmic therapies, with a clinical stage
portfolio in vascular retinal disorders, will be presenting
pre-clinical data from a study evaluating THR-687 for treatment of
diabetic macular edema (DME) at the upcoming Association for
Research in Vision and Ophthalmology (ARVO) Annual Meeting being
held in Denver, Colorado on May 1-4th and virtually on May 11-12th.
The presentation will review pre-clinical data supporting
THR-687 providing protection against retinal vascular permeability,
inflammation and reactive gliosis in the diabetic rat.
THR-687 is a highly selective pan-RGD integrin
antagonist that is initially being developed as a potential first
line therapy for DME patients and may have the potential to deliver
improved treatment outcomes for patients with wet macular
degeneration (wet AMD) and macular edema following retinal vein
occlusion (ME-RVO). Oxurion is currently evaluating THR-687
in a two-part Phase 2 clinical trial (“INTEGRAL”) in patients with
DME. Part A dose optimization data from the INTEGRAL trial is
anticipated in the first half of 2022. If successful, the efficacy
and safety of THR-687 versus aflibercept (the current standard of
care) will be evaluated in Part B of the INTEGRAL Phase 2 clinical
trial in both treatment-naïve and treatment-experienced patients
with DME. The pre-clinical data supports the view that
THR-687 provides protection in the diabetic rat against retinal
vascular permeability, inflammation and reactive gliosis.
Details of the presentation:
TITLE: THR-687, a potent
pan-RGD integrin antagonist, protects against retinal vascular
permeability, inflammation and reactive gliosis in the diabetic
rat
PRESENTER: Tine Van Bergen,
Senior Scientist, Oxurion NV
PRESENTATION DATE AND TIME:
Tuesday, May 3, 2022, 12:47 p.m. ET
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (wet AMD) and macular edema
following retinal vein occlusion (ME-RVO). Oxurion is aiming to
build a leading global franchise in the treatment of retinal
vascular disorders based on the successful development of its two
novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of DME patients showing suboptimal response to anti-VEGF
therapy. THR-687 is a highly selective pan-RGD integrin antagonist
that is being developed as a potential first line therapy for DME
patients as well as wet AMD and potentially ME-RVO. Oxurion is
headquartered in Leuven, Belgium, with corporate operations in
Boston, MA. More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 479
783583michael.dillen@oxurion.com |
EU MEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel:
+44 203 928 6900oxurion@medistrava.comUSICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com |
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024